SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.

马里兰州银泉市和北卡罗来纳州三角研究园——（商业新闻）——公共利益公司联合治疗公司（纳斯达克：UTHR）今天宣布，其商业和发展投资组合的最新研究将于2024年5月17日至22日在圣地亚哥举行的美国胸科学会（ATS）国际会议上发表。

At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum..

在ATS，联合治疗公司将主办一个关于在肺动脉高压中实施曲前列素诱导策略的教育行业剧院，该公司正在赞助ATS 2024女性论坛。。

“We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “Notably, our academic and industry collaborators will present initial interim efficacy data from the ADVANCE EXTENSION open label extension evaluating extended-release ralinepag for pulmonary arterial hypertension and baseline data updates for the ongoing TETON studies in idiopathic pulmonary fibrosis.

联合治疗公司（United Therapeutics）全球医疗事务副总裁安德鲁·内尔森（Andrew Nelsen）表示：“我们期待着提供有关我们几个关键产品和开发计划的最新数据。”。“值得注意的是，我们的学术和行业合作者将提供来自ADVANCE EXTENSION open label EXTENSION的初步中期疗效数据，该扩展评估了肺动脉高压的缓释ralinepag，以及正在进行的特发性肺纤维化TETON研究的基线数据更新。

We are also pleased to unveil the exciting preliminary findings from our collaboration with Tempus, a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.”.

我们也很高兴与人工智能和精准医学领域的领导者Tempus合作，公布了令人兴奋的初步发现，为早期识别肺动脉高压患者奠定了基础。”。

Posters, mini-symposia, and discussion sessions include:

海报、小型座谈会和讨论会包括：

Mini Symposium, Sunday, May 19, 10:03 to 10:15 a.m. PT: A14 – Metabolomic Signatures of Pulmonary Hypertension Associated with Interstitial Lung Disease: A Post-hoc Analysis of the INCREASE Study. Presented by Aaron B. Waxman, M.D., Ph.D., Brigham and Women’s Hospital.

小型研讨会，5月19日星期日，上午10:03至10:15。PT:A14–与间质性肺病相关的肺动脉高压的代谢组学特征：REGASE研究的事后分析。由布莱根妇女医院医学博士Aaron B.Waxman介绍。

Thematic poster session, Sunday, May 19, 11:30 a.m. to 1:15 p.m. PT: A46/P829 – Pulmonary Hypertension Screening Strategies in Patients with Interstitial Lung Disease: A Survey of PHINDER Study Sites. Presented by Eric Shen, PharmD, United Therapeutics.

主题海报会议，5月19日星期日上午11:30至下午1:15。PT:A46/P829–间质性肺病患者的肺动脉高压筛查策略：PHINDER研究地点的调查。由联合治疗公司PharmD Eric Shen介绍。

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1259 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

主题海报会议，5月20日星期一上午11:30至下午1:15。PT:B48/P1259–TETON吸入曲前列素治疗特发性肺纤维化的3期临床试验：初步基线数据的年度更新。由Inova Fairfax医院医学博士Steven D.Nathan介绍。

Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m. PT: B48/P1260 – Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.

主题海报会议，5月20日星期一上午11:30至下午1:15，PT:B48/P1260–吸入曲前列素治疗进行性肺纤维化的TETON-PPF临床试验的研究设计和基本原理。由Inova Fairfax医院医学博士Steven D.Nathan介绍。

Thematic poster session, Tuesday, May 21, 11:30 a.m. to 1:15 p.m. PT: C62/P284 – Real-World Transition and Persistence to Oral Treprostinil Therapy from Parenteral Prostacyclins in Patients with Pulmonary Arterial Hypertension. Presented by Ali Ataya, M.D., University of Florida.

主题海报会议，5月21日星期二，上午11:30至下午1:15。PT:C62/P284–肺动脉高压患者从肠外前列环素到口服曲前列环素治疗的现实世界转变和持续性。由佛罗里达大学医学博士Ali Ataya介绍。

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D105/410 – Clinical Improvements with Parenteral Induction Therapy in Intermediate-High Risk Patients With PAH: A Sub-Group Analysis of the EXPEDITE Study. Presented by Chad Miller, M.D., Piedmont Healthcare.

海报讨论会，5月22日，星期三，上午11:00至下午1:00。PT:D105/410–中高危PAH患者肠胃外诱导治疗的临床改善：EXPECTED研究的亚组分析。由Piedmont Healthcare医学博士Chad Miller介绍。

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D105/420 – Initial Long-term Data from a Phase 3 Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (ADVANCE EXTENSION). Presented by Joan A. Barberà, M.D., Ph.D., Hospital Clinic de Barcelona..

海报讨论会，5月22日，星期三，上午11:00至下午1:00，PT:D105/420–来自第三阶段开放标签扩展研究（ROR-PH-303）的初始长期数据，该研究评估了Ralinepag治疗肺动脉高压（提前扩展）。由巴塞罗那医院诊所医学博士Joan A.Barberà介绍。。

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/502 – Structured EHR Data Underestimates Prevalence and Misses Large Proportions of Patients with Pulmonary Hypertension. Presented by RuiJun Chen, M.D., Tempus.

海报讨论会，5月22日星期三，上午11:00至下午1:00。PT:D102/502–结构化EHR数据低估了患病率，并遗漏了大部分肺动脉高压患者。由Tempus医学博士陈瑞军（RuiJun Chen）介绍。

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/503 – A Novel Phenotyping Pipeline to Improve Identification of Patients with Pulmonary Hypertension in Electronic Health Records. Presented by David Vidmar, Ph.D., Tempus.

海报讨论会，5月22日，星期三，上午11:00至下午1:00。PT:D102/503–一种新的表型分析管道，用于改善电子健康记录中肺动脉高压患者的识别。由Tempus博士David Vidmar介绍。

Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/504 – ECG-based Machine Learning Model Identifies Patients at High Risk for Incident Pulmonary Hypertension. Presented by Greg Lee, Tempus.

海报讨论会，5月22日星期三，上午11:00至下午1:00。PT:D102/504–基于ECG的机器学习模型可识别发生肺动脉高压的高风险患者。由Tempus的Greg Lee介绍。

Sponsored events include:

赞助活动包括：

The ATS 2024 Women’s Forum, Monday, May 20, 11:45 a.m. to 1:15 p.m. PT featuring Zea Borok, M.D., ATSF, formerly of the University of Southern California; Stephanie Davis, M.D., ATSF, University of North Carolina at Chapel Hill; Sonia Buist, M.D, Oregon Health & Science University; and Obianuju Ozoh, M.D., University of Lagos..

ATS 2024妇女论坛，5月20日星期一上午11:45至下午1:15，由南加州大学前ATSF医学博士Zea Borok主持；Stephanie Davis，医学博士，ATSF，北卡罗来纳大学教堂山分校；俄勒冈州健康与科学大学医学博士Sonia Buist；和拉各斯大学医学博士Obianuju Ozoh。。

Industry Theater, Sunday, May 19, 12:30 to 1:00 p.m. PT – Implementing Treprostinil Induction Strategies in Pulmonary Hypertension. Presented by Chad Miller, M.D., Piedmont Healthcare.

工业剧院，5月19日星期日，下午12:30至1:00 PT–实施曲前列素诱导策略治疗肺动脉高压。由Piedmont Healthcare医学博士Chad Miller介绍。

United Therapeutics: Enabling Inspiration

联合疗法：激发灵感

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

在联合治疗公司，我们的愿景和使命是一体的。我们利用我们的热情、创造力和毅力来创新，以满足患者未满足的医疗需求，并使其他利益相关者受益。我们大胆而非传统。我们很开心，我们做得很好。我们是第一家以公益公司（PBC）形式上市的生物技术或制药公司。

Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs..

我们的公益目的是通过（a）开发新型药物疗法为患者提供更光明的未来；（b）扩大可移植器官可用性的技术。。

You can learn more about what it means to be a PBC here: unither.com/pbc.

你可以在这里了解更多关于PBC意味着什么：unither.com/PBC。

Forward-Looking Statements

前瞻性声明

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

本新闻稿中包含的非历史性声明是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。前瞻性声明包括，除其他外，我们的目标是创新以满足患者未满足的医疗需求，并使我们的其他利益相关者受益，进一步实现我们开发新型药物疗法和技术以扩大可移植器官可用性的公益目标。

These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

这些前瞻性陈述受到某些风险和不确定性的影响，例如我们向证券交易委员会提交的定期报告中所述的风险和不确定性，这可能导致实际结果与预期结果存在重大差异。因此，此类前瞻性陈述符合我们向证券交易委员会提交的定期报告和文件中规定的警告性陈述、警告性语言和风险因素，包括我们最近的10-K表年度报告、10-Q表季度报告和8-K表当前报告。

We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 16, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason..

我们要求保护1995年《私人证券诉讼改革法案》中所载的前瞻性声明的安全港。我们提供截至2024年4月16日的信息，不承担因新信息、未来事件或任何其他原因而更新或修订本新闻稿中包含的信息的义务。。